Research peptides are the obvious problem. But even within the medical-grade category, most providers quietly rely on the same cheap Chinese-sourced base compounds. Foundry RX is built differently.
The conversation around peptide safety usually stops at one distinction: research peptides versus medical-grade peptides. That distinction matters. But it is not the whole picture.
What the industry rarely discloses is what happens inside the medical-grade category. Most compounding pharmacies source their peptide base compounds from overseas manufacturers, predominantly China, because it is dramatically cheaper. The pharmacy may be US-licensed. The compounding process may meet cGMP standards. But the raw material entering that process often originates from the same bulk chemical supply chain as the research peptides everyone warns you to avoid.
That is the gap Foundry RX was built to close.
When you are evaluating peptide therapy, you are not choosing between two options. You are choosing between three, and the middle tier is where most "medical-grade" providers quietly operate.
| Research / grey market | Standard medical-grade | Foundry RX Top tier | |
|---|---|---|---|
| Base compound source | ✕ Overseas, unverified | — Often China-sourced, rarely disclosed | ✓ US-sourced ingredients, fully traceable |
| Compounding facility | ✕ Unregulated, overseas | — US-licensed, variable quality | ✓ 503B cGMP cleanroom, lot-traceable |
| Batch testing | ✕ None | — Varies by pharmacy | ✓ Identity, potency, sterility — every batch |
| Provider oversight | ✕ None | — Prescription required, limited follow-up | ✓ Licensed provider, 50-state telehealth |
| Sourcing transparency | ✕ None | — Rarely disclosed | ✓ Disclosed and verifiable |
| Human use labeling | ✕ "Not for human use" | — Prescribed, but base quality unverified | ✓ Fully compliant, full chain of custody |
Compounding a peptide means taking a raw base compound and processing it into a sterile, injectable form under controlled conditions. The US-licensed pharmacy handles that process. But the quality of what enters that process is only as good as the source it came from.
Chinese bulk peptide manufacturers operate at scale. Some maintain reasonable internal quality controls. Many do not. And because there is no FDA oversight of the raw material import stage at the level of individual compounding batches, a pharmacy can hold a valid US license and still be working with base compounds that have inconsistent purity, undisclosed additives, or degraded potency before the compounding process even begins.
A prescription does not tell you where the raw compound came from. Only the pharmacy's sourcing policy does, and most do not publish one.
The distinction Foundry RX makes is upstream. US-sourced ingredients means the base compounds entering our 503B compounding partner's facility are traceable, verified, and held to domestic quality standards before the compounding process begins. That is a different category of product than one assembled from cheaper imported raw materials at a licensed facility.
A 503B outsourcing facility is the highest regulatory tier for compounding pharmacies in the US. It means the facility operates under FDA inspection, follows cGMP manufacturing standards, and batch-tests every product before release. That is a meaningful standard.
But 503B certification governs the compounding process, not the origin of the inputs. Two 503B facilities can produce the same peptide at dramatically different quality levels depending entirely on where they source their base compounds. The certification tells you how the product was assembled. It does not tell you what it was assembled from.
Foundry RX uses a 503B partner and specifies US-sourced base compounds. Both matter. Neither alone is sufficient.
When assessing a telehealth or compounding pharmacy offering peptide therapy, the questions worth asking go beyond "do they require a prescription."
Ask where the base compounds are sourced. Ask whether the compounding facility is 503B certified. Ask for the Certificate of Analysis for the specific batch. Ask whether the provider can trace the lot number from raw material to finished vial. A provider operating at the highest standard of care will answer all of these without hesitation. Most will not answer them at all.
Silence on sourcing is an answer.
The right question is not just whether your peptides are medical-grade. It is where the medicine was made, from what, and who can prove it.
Every protocol available through Foundry RX is prescribed by a licensed provider, compounded at a US 503B facility, and formulated from US-sourced ingredients with full lot traceability. We do not offer the most convenient path into peptide therapy. We offer the most defensible one.
Medical-grade is the floor. This is the ceiling.
Begin a protocol built on verified compounds, domestic sourcing, and clinical oversight.
Start your intakeThis content is for informational purposes only and does not constitute medical advice. All Foundry RX treatments require a consultation with a licensed provider and are subject to clinical approval. Individual results vary.